Live Attenuated Vaccines Global Market Report 2025

The live attenuated vaccines market size has grown rapidly in recent years. It will grow from $23.58 billion in 2024 to $25.95 billion in 2025 at a compound annual growth rate (CAGR) of 10.1%. The growth during the historic period can be attributed to the expansion of global immunization coverage, increased public health expenditure, heightened awareness about disease prevention, rising demand for pediatric vaccines, and the broadening of vaccination initiatives and programs.

The live attenuated vaccines market size is expected to see strong growth in the next few years. It will grow to $37.56 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%. The projected growth in the forecast period can be attributed to an increased emphasis on preventive healthcare, broader adoption of vaccines in low- and middle-income countries, enhanced support for outbreak preparedness, rising demand for travel-related vaccinations, and the expansion of government-funded immunization initiatives. Key trends expected during this period include advancements in vaccine delivery technologies, innovations in genetic attenuation methods, increased investment in research and development, the creation of thermostable vaccine formulations, and the integration of digital technologies into immunization programs.

The rising prevalence of infectious diseases is expected to drive significant growth in the live attenuated vaccines market. Infectious diseases - caused by bacteria, viruses, fungi, or parasites - can spread rapidly, particularly due to increased global travel, which facilitates faster transmission of pathogens across borders. Live attenuated vaccines play a critical role in combating these diseases by inducing strong, long-lasting immune responses using weakened forms of the pathogens, thereby offering effective protection and helping curb outbreaks. For example, in March 2025, the World Health Organization reported that in 2023, approximately 10.8 million people contracted tuberculosis (TB) globally, including 6 million men, 3.6 million women, and 1.3 million children. This growing burden of infectious diseases underscores the essential role of live attenuated vaccines in global disease prevention, fueling market expansion.

Major companies in the live attenuated vaccines market are increasingly focusing on developing innovative solutions such as single-dose vaccines to improve immunization outcomes and patient adherence. Single-dose vaccines offer durable immunity with just one injection, streamlining vaccination protocols and reducing logistical challenges for healthcare systems. This approach improves patient compliance by eliminating the need for follow-up doses. For example, in November 2023, Valneva SE, a France-based biotechnology company specializing in vaccines for infectious diseases, launched IXCHIQ, the world’s first live-attenuated vaccine for chikungunya. The vaccine received approval from the U.S. Food and Drug Administration (FDA) for use in adults aged 18 and older. IXCHIQ addresses a critical unmet need by offering protection against chikungunya - a mosquito-borne viral infection known for causing high fever, joint and muscle pain, and other debilitating symptoms. This approval marks a significant advancement in the field of live attenuated vaccines and highlights the industry's shift toward convenient, single-dose immunization strategies.

In May 2023, Bavarian Nordic A/S, a Denmark-based biotechnology company, acquired the travel health business of Emergent BioSolutions Inc. for approximately $380 million. This strategic acquisition aims to broaden Bavarian Nordic’s vaccine portfolio by including key products such as VIVOTIF (for typhoid fever), VAXCHORA (for cholera), and the CHIKV VLP chikungunya vaccine candidate. The deal also includes the acquisition of manufacturing and development facilities located in Switzerland and California, enhancing the company’s production capabilities and global footprint. Emergent BioSolutions Inc., a US-based biopharmaceutical company, is known for manufacturing live attenuated vaccines and other infectious disease solutions.

Major players in the live attenuated vaccines market are Merck & Co. Inc., Sanofi SA, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, CSL Limited, GC Biopharma, Serum Institute of India Pvt. Ltd., Bavarian Nordic, Valneva SE, Southern Research, BioFarma, Bharat Biotech International Limited, Meissa Vaccines Inc., BioDiem Ltd., Bio-Med Limited, Naobios, Lakshmi Pharmaceuticals.

North America was the largest region in the live attenuated vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in live attenuated vaccine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the live attenuated vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Live attenuated vaccines are biological preparations that contain a weakened form of a virus or bacterium, designed in a laboratory to ensure it does not cause illness in healthy individuals. These vaccines closely mimic a natural infection, thereby stimulating a strong and long-lasting immune response, often requiring just one or two doses to provide effective protection against infectious diseases.

The primary categories of live attenuated vaccines include monovalent and multivalent types. Monovalent vaccines are formulated to target a single specific antigen, strain, or type. These vaccines are administered through various routes, including intramuscular, subcutaneous, oral attenuated, and intranasal attenuated methods. They are used to prevent diseases such as influenza, measles, mumps, rubella (MMR), polio, chickenpox, shingles, rotavirus, and others. Distribution occurs through hospital pharmacies, retail pharmacies, and online pharmacies, with end-users including hospitals, clinics, diagnostic centers, research institutes, and more.

The live attenuated vaccines market research report is one of a series of new reports that provides live attenuated vaccines market statistics, including the live attenuated vaccines industry global market size, regional shares, competitors with the live attenuated vaccines market share, detailed live attenuated vaccines market segments, market trends, and opportunities, and any further data you may need to thrive in the live attenuated vaccines industry. These live attenuated vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The live attenuated vaccine market consists of sales of viral live attenuated vaccines, bacterial live attenuated vaccines, and intranasal live attenuated vaccines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.